United States //   News Releases

News Releases

News Releases

Date Title and Summary Additional Formats
Toggle Summary Endologix Announces Completion of Enrollment in the EVAS2 Confirmatory Clinical Study to Evaluate the Nellix EndoVascular Aneurysm Sealing System
IRVINE, Calif. --(BUSINESS WIRE)--May 11, 2020-- Endologix ® Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that it has completed enrollment in the EVAS2 Confirmatory Clinical Study to Evaluate the Nellix
View HTML
Toggle Summary Endologix Reports First Quarter 2020 Financial Results
IRVINE, Calif. --(BUSINESS WIRE)--May 11, 2020-- Endologix, Inc. (the “Company”) (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced its financial results for the first quarter ended March 31, 2020 . The Company’s financial results are preliminary
View HTML
Toggle Summary Endologix, Inc. to Announce First Quarter 2020 Financial Results on May 11, 2020
IRVINE, Calif. --(BUSINESS WIRE)--May 1, 2020-- Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the first quarter of fiscal year 2020 after the market close on Monday, May 11, 2020 .
View HTML
Toggle Summary Endologix Appoints Tim A. Benner as Chief Commercial Officer
IRVINE, Calif. --(BUSINESS WIRE)--Apr. 14, 2020-- Endologix, Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed Tim A. Benner to succeed John Zehren as the Company’s Chief Commercial
View HTML
Toggle Summary Endologix Announces Preliminary Financial Results for First Quarter 2020
IRVINE, Calif. --(BUSINESS WIRE)--Apr. 6, 2020-- Endologix, Inc. (the “Company”) (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that its preliminary unaudited revenue for the first quarter ended March 31, 2020 is expected to be approximately
View HTML
Toggle Summary Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
IRVINE, Calif. --(BUSINESS WIRE)--Mar. 30, 2020-- Endologix, Inc. (Nasdaq: ELGX) (the “Company”), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to two newly hired employees (the “Awardees”).
View HTML
Toggle Summary Endologix Adds Jane E. Kiernan to its Board of Directors
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed Jane E. Kiernan to its board of directors, effective March 12, 2020 . Ms.
View HTML
Toggle Summary Endologix Receives FDA Approval for Alto Abdominal Stent Graft System
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix ® Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that it has received approval from the United States Food and Drug Administration (FDA) for the Alto™ Abdominal
View HTML
Toggle Summary Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq: ELGX) (the “Company”), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of an inducement equity award to a newly hired employee (the “Awardee”).
View HTML
Toggle Summary Endologix Announces Debt Restructuring Addressing 2020 Maturities
IRVINE, Calif. --(BUSINESS WIRE)--Feb. 24, 2020-- Endologix, Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, announced today that it has entered into an exchange agreement with three holders of the Company’s 3.25% Senior
View HTML
Toggle Summary Endologix Reports Fourth Quarter and Fiscal Year 2019 Financial Results
IRVINE, Calif. --(BUSINESS WIRE)--Feb. 19, 2020-- Endologix, Inc. (the “Company”) (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the fourth quarter and fiscal year ended December 31, 2019 .
View HTML
Toggle Summary Endologix, Inc. to Present at the SVB Leerink Global Healthcare Conference
IRVINE, Calif. --(BUSINESS WIRE)--Feb. 18, 2020-- Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that Vaseem Mahboob , Chief Financial Officer, will present at the 9 th Annual SVB Leerink Global Healthcare Conference at 3:00
View HTML
Toggle Summary Endologix Announces Preliminary Financial Results and Conference Call for Fourth Quarter and Full-Year 2019
IRVINE, Calif. --(BUSINESS WIRE)--Feb. 6, 2020-- Endologix, Inc. (the “Company”) (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that its preliminary unaudited revenue for the fourth quarter ended December 31, 2019 is expected to be
View HTML
Toggle Summary Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
IRVINE, Calif. --(BUSINESS WIRE)--Feb. 3, 2020-- Endologix, Inc. (Nasdaq: ELGX) (the “Company”), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of an inducement equity award to a newly hired employee (the “Awardee”).
View HTML
Toggle Summary Endologix, Inc. to Present at the J.P. Morgan Healthcare Conference
IRVINE, Calif. --(BUSINESS WIRE)--Jan. 2, 2020-- Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John Onopchenko , Chief Executive Officer, and Vaseem Mahboob , Chief Financial Officer, will present at the 38 th Annual
View HTML